Indeed, IDH1 silencing in glioma cells that display co-activation of multiple RTKs (EGFR, the HGFR family member MSPR, and PDGFRs) enhances the efficacy of inhibitor combinations involving erlotinib, imatinib, and SU11274 [65]. The gene discussed is EGFR; the disease is glioma.